What's Up At Ionis Pharmaceuticals (IONS) In Q1 Earnings?
Zacks Investment Research | May 01, 2016 11:37PM ET
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is scheduled to report first-quarter 2016 results on May 4.
Ionis’ track record has been disappointing so far. Over the four trailing quarters, the company posted an average negative earnings surprise of 1.21%, having beaten estimates in two quarters and missed it in the other two.
Let’s see how things are shaping up for the first quarter of 2016.
Factors to Consider
Ionis has partnerships with several leading health care companies like Biogen Inc. (NASDAQ:BIIB) and GlaxoSmithKline plc (NYSE:GSK) among others that not only validate its technology platform but also provide the company with a steady stream of funds in the form of upfront, milestone and other payments.
At the time of announcing fourth-quarter 2015 results, Ionis revealed that it had already earned $7 million in milestone payments from Biogen for progressing on the phase III program on nusinersen and on IONIS-BIIB4RX; and from Glaxo for initiating a phase I study on IONIS-HBV-LRX. This should aid revenues in the first quarter of 2016.
We remind investors that the company’s revenues fluctuate on the basis of the timing of payments under agreements with its partners.
In the to-be-reported quarter, investor focus should remain on the company’s pipeline development which includes three phase III candidates – IONIS-TTRRx (transthyretin amyloidosis), nusinersen (spinal muscular atrophy in infants and children) and volanesorsen (familial chylomicronemia syndrome and familial partial lipodystrophy). In addition, the company has several early- to mid- stage candidates.
Earnings Whispers?
Our proven model does not conclusively show that Ionis is likely to beat estimates this quarter. That is because a stock needs to have both a positive Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.